Immix Biopharma

Update in progress

IMMX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Immix Biopharma is a clinical-stage biopharmaceutical company developing chimeric antigen receptor (CAR) cell therapies for light chain amyloidosis and immune-mediated diseases in the United States and Australia. Its lead product candidate is NXC-201 for relapsed or refractory AL amyloidosis. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Company score

Sentiment: 0.42; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.42; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.28; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive